The clinical effectiveness and cost effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women AND Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Appeal

The Institute has arranged a hearing for three appeals received against the Final Appraisal Determination and Guidance on this technology.

As set out in the Guidance for Appellants members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of observers admitted to the hearing will be limited to a number appropriate for the venue, and priority will be given to members of the public who are not employed by the appellants.

A hearing will be held at NICE, MidCity Place, 71 High Holborn, London WC1V 6NA, on 22 October 2007 starting at 9.30am.

Members of the public will be able to register to attend the appeal hearing from 18 September 2007. The Institute will not accept early requests to attend.

If you have any special requirements that will facilitate your attendance (such as disabled access or a hearing loop) please let us know.

The names of the appellants will be published on this page on the day of the appeal.  The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institute’s website.

• Appeal against the clinical and cost effectiveness of technologies for the primary and secondary prevention of osteoporosis